Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials

Overview of attention for article published in Frontiers in endocrinology, March 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,172 followers.

RT @FrontEndocrinol: New Research: Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes:…

29 Mar 2023

Reply Repost Favourite

New Research: Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials: Background Pioglitazone is considered a potential therapy for… https://t.co/vst3rDyw6U

29 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.